Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics strengthens financial management with key appointment to enable progress to market access
VasoDynamics strengthens financial management with key appointment to enable progress to market access 3rd September 2024 - VasoDynamics Ltd, the pharmaceutical company developing preventive therapies for
VasoDynamics strengthens the Board with key appointments
VasoDynamics strengthens the Board with key appointments Building a strong Board of industry experts to enable progress to market acces • Dr Laurence Reilly, Non-executive Chair
NG11-2 Phase-Ib Study Completes Last Patient Visit
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer.
VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference
At the recent ESTRO conference in Glasgow on 3-7 May 2024, VasoDynamics presented the preliminary findings from its Phase-1b Study with NG11-2.
VasoDynamics Receives Global Health & Pharma Biotechnology 2024 Award
VasoDynamics receives Global Heath & Pharma Biotechnology Award 2024 as Best Cancer Care Solutions Provider 2024 - UK